| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13G · 2 securities · passive | ||||||
|
TScan Therapeutics, Inc.
13G
TCRX · 89854M101
|
5.4% |
9/25/2026
Event 9/21/2026
|
||||
| Readout Capital, LP | 5.4% | |||||
| Readout Capital GP, LLC | 5.4% | |||||
| Matthew Smith | 5.4% | |||||
|
Precision BioSciences, Inc.
13G/A
DTIL · 74019P207
|
9.4% |
8/14/2025
Event 6/30/2025
|
||||
| Readout Capital, LP | 9.3% | |||||
| Readout Capital GP, LLC | 9.3% | |||||
| ROC Holdings SPV II, LP | 7.6% | |||||
| Readout Holdings GP, LLC | 7.6% | |||||
| Matthew Smith | 9.4% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.